Ovarian Cancer Research Fund (OCRF), founded in 1994, is the oldest and largest charity in the United States funding ovarian cancer research, and ranks third in overall ovarian cancer research funding. Our mission is to fund scientific research that leads to more effective identification, treatment, and ultimately a cure for ovarian cancer. Thanks to the generosity of our individual donors, foundations, and corporate partners, our investigators are developing innovative strategies for early detection; exploring the genetics that increase risk for ovarian cancer; understanding the underlying molecular biology of the disease; identifying new and better targets for treatment; and deciphering how and why ovarian cancer spreads, and how to stop it.
OCRF has invested over $57 million in ovarian cancer research through 217 grants to scientists at 65 leading medical centers in the United States. Eighty-seven percent (87%) of every dollar raised supports our programs, earning OCRF a coveted four-star ranking from the independent charity evaluator, Charity Navigator. In 2012, and again in 2013, OCRF received the most applications in the organization’s history.
Cancer is a complex disease, and making scientific advancements requires an extensive and continuing investment in laboratory research. The majority of ovarian cancer research funding in the United States comes from two government sources—the National Cancer Institute or the Department of Defense. Unfortunately, federal funding for ovarian cancer research has been stagnant for many years and the grant process can be lengthy.
OCRF is different–more nimble in funding the most novel approaches, OCRF is able to solicit, review, and fund worthy applications in a relatively short time frame, which not only leads to more rapid scientific progress, but facilitates the professional growth of the most promising new investigators in the field of ovarian cancer. Without sufficient grant support, researchers might otherwise turn their attention to other, better funded diseases. OCRF funding effectively enhances the breadth of the research enterprise in this nation directed specifically to ovarian cancer research. And all OCRF research grants are approved by our world-class Scientific Advisory Committee comprised of leaders in the field, thus ensuring the integrity and caliber of the selections.
In 2012, OCRF launched a national support program, Woman to Woman, for women undergoing treatment for gynecologic cancer. This unique program, originally founded at Mount Sinai Medical Center in Manhattan, pairs women who have undergone treatment with women who are currently going through it. With the support of our longtime partner, QVC, sites have been established at NewYork-Presbyterian Hospital (New York, NY), Duke Cancer Institute (Chapel Hill, NC), Smilow Cancer Hospital at Yale (New Haven, CT), Stanford University (Stanford, CA) and Moffitt Cancer Center (Tampa, FL). OCRF also continues to support the original program at Mount Sinai (New York, NY).
With your support, OCRF continues to take the lead in funding the best and most promising ovarian cancer research while supporting women and their loved ones affected by the disease in our quest to end this terrible disease.